STING1 and acute myeloid leukemia: Notably, Venetoclax has recently been shown to augment T-cell effector function by increasing the production of reactive oxygen species and Azacitidine has been shown to enhance sensitivity of AML cells to cytotoxic T-cells by activating the STING pathway (Lee et al., 2021).